Company

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
Auto-immuneBioPartners X

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X announced that it has entered into a technology transfer agreement with the Hospital of Dermatology, Chinese Academy of Medical Sciences (CAMS) for an innovative CD132‑targeting monoclonal antibody, with…

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Zai Lab's ZL-1310 Receives FDA Fast Track Designation for SCLC
ADC / XDCHKG: 9688

Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC

Porton and Hualong Biological Partner to Advance MATC Therapy
Cell-therapyCRO / CMO / CDMO

Porton and Hualong Biological Partner to Advance MATC Therapy

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment
AB ScienceCOVID-19

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment

4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials
4B TechnologiesClinical trial approval / initiation

4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials

Show More